21 Nov 2025 | 3 Mins Read
Natco Pharma receives seven FDA observations at Manali API unit
Flipitmoney
US FDA concluded its inspection of Natco Pharma's API manufacturing facility in Chennai, identifying 7 procedural Form 483 observations. The company is confident of addressing them. Natco reported a 23.5% net profit drop in Q2, with revenue and EBITDA also declining. The company declared an interim dividend of ₹1.50 per share for FY26.